Background Several genes are candidates for treating inner ear diseases. For clinical
applications, minimally invasive approaches to the inner ear are desirable along with …

More than 28 million Americans suffer from various forms of hearing loss. The lack of
effective treatments for many forms of hearing disorders has prompted interest in the …

Development of a viral vector that can infect hair cells of the cochlea without producing viral-
associated ototoxic effects is crucial for utilizing gene replacement therapy as a treatment for …

The adeno-associated virus (AAV), inoculated into the perilymph, has been shown to be an
effective vector for mediating intracochlear transgene expression. The unexpected finding of …

Hearing loss, including genetic hearing loss, is one of the most common forms of sensory
deficits in humans with limited options of treatment. Adeno-associated virus (AAV)-mediated …

Murine models are ideal for studying cochlear gene transfer, as many hearing loss-related
mutations have been discovered and mapped within the mouse genome. However, because …

Targeting specific cell types in the mammalian inner ear is important for treating genetic
hearing loss due to the different cell type-specific functions. Adeno-associated virus (AAV) is …

Objectives/Hypothesis Gene therapy offers the possibility of delivering corrective genetic
materials to the cochlea, potentially improving hearing. In animals, the most commonly used …

Adeno-associated virus (AAV) integrated transgene expression within guinea pig cochlea
has been previously documented. This article extends these studies by characterizing the …

There are a number of genetic diseases that affect the cochlea early in life, which require
normal gene transfer in the early developmental stage to prevent deafness. The delivery of …